Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 TrialBusiness Wire • 04/10/21
Is Bristol Myers Stock A Buy As Opdivo Faces An FDA Hurdle In April?Investors Business Daily • 04/09/21
CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal.Business Wire • 04/08/21
Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal CancerBenzinga • 04/08/21
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 04/08/21
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology CollaborationBusiness Wire • 04/07/21
Is Bristol Myers Squibb (BMY) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/06/21
Bristol Myers In Over $1B Tax Brawl After Accidental Disclosure Of Offshore Patents Setup: NYTBenzinga • 04/01/21
Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In MelanomaPRNewsWire • 03/30/21
Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX HighlightsBusiness Wire • 03/30/21
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial CarcinomaBusiness Wire • 03/29/21
Bristol Myers Squibb's Floundering Days Could Be Behind It - Full Steam AheadSeeking Alpha • 03/28/21